Kidney protection with the radical scavenger α1-microglobulin (A1m) during peptide receptor radionuclide and radioligand therapy

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

α1-microglobulin (A1M) is an antioxidant found in all vertebrates, including humans. It has enzymatic reductase activity and can scavenge radicals and bind free heme groups. Infused recombinant A1M accumulates in the kidneys and has therefore been successful in protecting kidney injuries in different animal models. In this review, we focus on A1M as a radioprotector of the kidneys during peptide receptor radionuclide/radioligand therapy (PRRT/RLT). Patients with, e.g., neuroendocrine tumors or castration resistant prostate cancer can be treated by administration of radiolabeled small molecules which target and therefore enable the irradiation and killing of cancer cells through specific receptor interaction. The treatment is not curative, and kidney toxicity has been reported as a side effect since the small, radiolabeled substances are retained and excreted through the kidneys. In recent studies, A1M was shown to have radioprotective effects on cell cultures as well as having a similar biodistribution as the somatostatin analogue peptide177Lu-DOTA-TATE after intravenous infusion in mice. Therefore, several animal studies were conducted to investigate the in vivo radioprotective potential of A1M towards kidneys. The results of these studies demonstrated that A1M co-infusion yielded protection against kidney toxicity and improved overall survival in mouse models. Moreover, two different mouse studies reported that A1M did not interfere with tumor treatment itself. Here, we give an overview of radionuclide therapy, the A1M physiology and the results from the radioprotector studies of the protein.

Originalspråkengelska
Artikelnummer1271
Sidor (från-till)1-18
TidskriftAntioxidants
Volym10
Utgåva8
DOI
StatusPublished - 2021

Bibliografisk information

Funding Information:
This work was funded by the Swedish Cancer Society (grant no. 190470Pj), the Swedish Research Council (VR; grant no. 2017-00696), the Swedish Prostate Cancer Federation, Swedish Foundation for Strategic Research (SSF), the Royal Physiographic Society in Lund, and the Clinic of Oncology in Lund?s research foundation. Research grants from Guard Therapeutics International (formerly A1M Pharma AB) and Berta Kamprad?s Foundation (grant no. FBKS-2021-33-(348).

Funding Information:
Funding: This work was funded by the Swedish Cancer Society (grant no. 190470Pj), the Swedish Research Council (VR; grant no. 2017-00696), the Swedish Prostate Cancer Federation, Swedish Foundation for Strategic Research (SSF), the Royal Physiographic Society in Lund, and the Clinic of Oncology in Lund’s research foundation. Research grants from Guard Therapeutics International (formerly A1M Pharma AB) and Berta Kamprad’s Foundation (grant no. FBKS-2021-33-(348).

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Ämnesklassifikation (UKÄ)

  • Radiologi och bildbehandling

Fingeravtryck

Utforska forskningsämnen för ”Kidney protection with the radical scavenger α1-microglobulin (A1m) during peptide receptor radionuclide and radioligand therapy”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här